Tuesday, September 20, 2016 11:50:37 AM
Rereading what I stated, I think I was picking on the Analyst’s for not delving deeper into what SPPI presents. Looking back on that, I think I’m too harsh on the Analysts. Yes, it’s frustrating that they don’t dig deeper but I think I read somewhere that Analysts are invited to meetings at the discretion of the company. Not sure how true that is but at the very least if they are looking to get some business from the company that for sure won’t happen if you give company management a rough time at these quarterly’s. Thinking about it, I’m more inclined to give management much more fault for not being more open and honest when they discuss these half-truths but still is frustrating that better Qs aren’t asked.
Second, regarding using autologous HSCTs and melphalan on the sickest MS pts (20,000), well that almost triples, not doubles, the # of pts that would be able to get Evomela if it became the ‘per label’ drug for that use. And while the reference I gave yesterday did not use melphalan this other P2 study with similar results did.
Recent SPPI News
- Form 15-12G - Securities registration termination [Section 12(g)] • Edgar (US Regulatory) • 11/09/2023 10:00:17 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 09/28/2023 04:15:27 AM
- Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments • Edgar (US Regulatory) • 09/26/2023 09:23:08 PM
Avant Technologies Engages Wired4Tech to Evaluate the Performance of Next Generation AI Server Technology • AVAI • May 23, 2024 8:00 AM
Branded Legacy, Inc. Unveils Collaboration with Celebrity Tattoo Artist Kat Tat for New Tattoo Aftercare Product • BLEG • May 22, 2024 8:30 AM
"Defo's Morning Briefing" Set to Debut for "GreenliteTV" • GRNL • May 21, 2024 2:28 PM
North Bay Resources Announces 50/50 JV at Fran Gold Project, British Columbia; Initiates NI 43-101 Resources Estimate and Bulk Sample • NBRI • May 21, 2024 9:07 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM